publication date: Jul. 24, 2020

Lowy: COVID-19 pandemic inspired new “shortcuts” in NCI clinical trials

By Alexandria Carolan

This story is part of The Cancer Letter’s ongoing coverage of COVID-19’s impact on oncology. Our full coverage of SARS-CoV2 is available here.

Adjusting to the pandemic, NCI has developed shortcuts in the conduct of clinical trials that could make it easier to conduct clinical trials, NCI Principal Deputy Director Douglas Lowy said at the virtual meeting of the American Association for Cancer Research on COVID-19 and Cancer.

“Because of the COVID-19 epidemic, we have made a number of shortcuts that we believe have been essential in enabling us to enroll patients quickly, but without compromising quality,” Lowy said during the session on COVID-19 Diagnostics Development. “And we are optimistic that at least some of these shortcuts will be able to be employed as we go forward even after the COVID-19 epidemic ends.”

Lowy spoke at the July 20-22 virtual meeting on COVID-19 and Cancer, during the session on COVID-19 Diagnostics Development.

The shortcuts are:

Informed consent—which can be done remotely,

Patients not required to have extra visits for the study,

Research blood specimens collected when blood is drawn as part of regular clinical care,

Imaging scans collected for banking as part of clinical care,

Research blood tests that do not require onsite processing,

At-home specimen kits that include shipping to the biorepository,

Sites receive full accrual credit for enrollments to Step 1, partial credit for Step 0, per the ETCTN, NCORP, NCTN guidelines.

“We believe the COVID-19 epidemic may also stimulate modified approaches to cancer screening,” … Continue reading Lowy: COVID-19 pandemic inspired new “shortcuts” in NCI clinical trials

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.